United States: In re Ethicon: Connecting Seemingly Unrelated Dots May Support An Obviousness Conclusion

Composition claims are often rejected as obvious over the combinations of prior art referenced, that separately claim the ingredients of the claimed combination. Moreover, often the disclosure of the claimed ingredients is in the context of different chemical applications. In such cases, the obviousness determination frequently turns on whether one of ordinary skill in the art would have been motivated to combine the references to arrive at the claimed invention with a reasonable expectation of success. The inquiry is highly factual and can lead to different results, depending on the perspective of the fact finder. The Federal Circuit opinion in In re Ethicon —and Judge Newman's dissent—illustrate the difficulty of this inquiry. 844 F.3d 1344, 1354 (Fed. Cir. 2017).

Ethicon, Inc. ("Ethicon") owns U.S. Patent No. 7,591,844, which relates to drug-eluting stents, and methods for maintaining drugs on them. In relevant part, the claims are directed to "[a] device for intraluminal implantation in a vessel comprising a balloon-expandable stent and a pharmaceutical agent-containing coating, said coating comprising a biocompatible polyfluoro copolymer that comprises about eighty-five weight percent vinylidinefluoride [VDF] copolymerized with about fifteen percent hexalfluoropylene [HFP] . . . ." See '844 patent col. 37, l. 59-col. 38, l. 3. (Emphasis added). Ethicon sued Boston Scientific SCIMED ("Boston Scientific") and Abbott Laboratories ("Abbott") for infringement. In re Ethicon, 844 F.3d at 1354. Boston Scientific and Abbott filed separate requests for inter partes reexamination of the '844 patent. The Patent Office granted the reexamination requests and merged the proceedings. Id. In reexamination, the examiner rejected the relevant claims as obvious over, inter alia, U.S. Patent Nos. 5,824,048 ("Touch"), 4,816,339 ("Tu"), and 3,178,399 ("Lo").  Id.

Tuch, the primary reference, is generally directed to polymer coated drug-eluting vascular stents and names hundreds of monomers encompassing thousands of polymers and copolymers that may all be usable for vascular stents in various conditions. Id. at 1353 (Newman J., dissenting). Tuch, however, not disclose the specific copolymer claimed in the Ethicon patent. And although the list in Tuch discloses one of the monomers of the claimed copolymer (VDF), the other known monomer, HFP, is not mentioned. Id. Tu, in turn, describes a multilayered "suturable vascular implants" having "improved luminal hydrophobicity, compliance, strength and elasticity." Id. at 1355 (emphasis added).  The first layer is made of poly(tetrafluoroethylene), the second layer is "a mixture of poly(tetrafluoroethylene) and elastomer," and an optional third layer is made of "elastomer." Id. Tu states that the elastomer may be selected from a diverse group of polymers and copolymers, and VDF and HFP were listed among this list. Id. (citing to Tu, col. 4, ll. 30-39.). The Examiner relied on Tu "for teaching of a medical device comprising VDF:HFP," and further  relied on Lo to teach the VDF:HFP comonomer ratios claimed in the Ethicon patent. Id. at 1357. The Examiner also found unpersuasive Ethicon's evidence of objective indicia of non-obviousness. See id.

The Board affirmed the Examiner's rejection. Id. at 1348. The Board found that the primary reference's teachings would not have limited a skilled artisan to the explicitly listed polymers or dissuaded a skilled artisan from selecting a VDF copolymer. Id. The Board additionally found that the primary reference discloses "a problem with coatings with low elasticity," and that biocompatibility and elasticity are "useful" characteristics for the polymer in its stent coatings and that, therefore, one of ordinary skill in the art would have reasonably sought materials with high elasticity to avoid the problem when the stent is expanded." Id. Among other things, the Board agreed that Tu, one of the secondary references, teaches that VDF:HFP copolymer possesses the useful properties of biocompatibility and elasticity taught by Tuch. Id. The Board similarly agreed that Lo teaches that the claimed monomer ratio "is advantageous with respect to flexibility, elasticity, extensibility, tensile strength, and reverse elongation." See id. The Board agreed with the Examiner that Ethicon's evidence of nonobviousness was not entitled to substantial weight. Id.

On appeal, Ethicon first argued that Tuch never suggested that the elasticity of the polymer itself is an important characteristic and that it, in fact, taught away from using non-bioabsorbable coatings (such as VDF:HFP) by recommending bioabsorbable polymers. Id. The court rejected Ethicon's argument finding that Tuch teaches that elasticity is a useful polymer characteristic and that coatings with low elasticity are problematic. Id. at 1350. Second, Ethicon argued that Tu is directed to medical devices, other than stents, and teaches away from allowing an elastomeric polymer such as VDF:HFP to be in contact with blood. Id. at 1351. The court also rejected this argument, finding that Tu teaches that its invention has a "very broad application in biomedical devices, such as ... heart valve leaflets," Id. Third, Ethicon argued that Lo is decades old (over 50 years old), nonanalogous art directed to harsh industrial applications, as opposed to medical or biological applications, and provides no motivation to combine its teachings with the teachings of Tuch or Tu (dealing with implantable medical devices). Id. Thus, Ethicon essentially argued that the Board relied on impermissible hindsight and failed to provide any reason why one of ordinary skill in the art would have combined the prior art references to create the claimed invention.  Id. The court rejected this argument and determine that substantial evidence supports the Board's finding that Lo's teachings are at least "reasonably pertinent to the particular problem with which the inventors is involved," and stated that the mere age of a reference does not undermine the Board's otherwise proper reliance on it. Id.

The Court also rejected Ethicon's argument that the Board erred by discounting its proffered objective indicia of nonobviousness, because Ethicon relied solely on its expert's conclusory testimony to support its allegations. Id.

Judge Newman dissented concluding that there was no motivation to combine the references without hindsight and finding that the Board erred in declining to consider Ethicon's evidence of copying, commercial success, and medical industry acclaim. Id. at 1353. Judge Newman found that the main reference's omission of the specific copolymer claimed from the thousands of polymeric and other potential stent materials was problematic. According to Judge Newman, "the breadth of these choices and the numerous combinations indicate that these disclosures would not have rendered the claimed invention obvious to try." Id. at 1354 (citing LeoPharma Prods., Ltd. v. Rea, 726 F.3d 1346, 1356–57 (Fed. Cir. 2013)). Judge Newman further disagreed with the Board's combination of the references to arrive at the claims because the references failed to provide motivation to select specific polymer and monomer ratio claimed by Ethicon. See id.

According to Judge Newman, the Board merely collected the elements of Ethicon's patent claims from assorted sources, and improperly placed them in the template of Ethicon's patent. See id. at 1357(citing to Interconnect Planning Corp. v. Feil, 774 F.2d 1132, 1138 (Fed. Cir. 1985) ("The invention must be viewed not with the blueprint drawn by the inventor, but in the state of the art that existed at the time.").

Judge Newman also took issue with the Board's refusal to consider the evidence of superior properties and commercial success presented by Ethicon. The Board, for example, declined to consider the evidence without identifying what it would consider to be an acceptable prior art comparison. Id. To Judge Newman, the Board's refusal to consider this evidence, instead criticizing the "absence" of comparisons with some undefined prior art, is untenable. Id.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
15 Nov 2017, Conference, California, United States

Finnegan is a Gold sponsor of the second annual Digital Media & IP Forum, hosted by World Congress.

15 Nov 2017, Conference, London, UK

Finnegan partner Leythem Wall will consider European claim drafting strategy and will lead the Chemical Workshop during a two-day course, hosted by Management Forum.

15 Nov 2017, Seminar, Amsterdam, Netherlands

Finnegan partner Anthony Tridico will lead Forum Institute for Management’s course comparing patent law in the United States and Europe.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.